UNSPSC 51162634: Isoaminile citrate

This classification denotes an antitussive agent with the molecular formula C16H24N2.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 27K34XSD46, chemically known as valeronitrile, 4-(dimethylamino)-2-isopropyl-2-phenyl-, citrate but more generally known as isoaminile citrate, which bears US NIH Compound Identifier 161602. European Medicines Agency schedules Isoaminile citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02783MIG.

Most nations, for tariff and trade purposes, schedule isoaminile citrate under HS 29269095 and SITC 51484. As of Q4 2014, ISOAMINILE CITRATE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)C(CC(C)N(C)C)(C#N)C1CCCCC1.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.

UNSPSC 51162634 Isoaminile citrate is a Commodity code that maps to pharmaceutical and over-the-counter health products procured by state and local health agencies, though recent activity under this specific code shows limited direct alignment with the nominal product name. State and local governments soliciting under this classification seek pharmaceutical inventories—including naloxone, generic multi-source pharmaceuticals, and OTC products—for community health initiatives, emergency response, and inter-agency distribution networks. Issuing bodies include county health departments and cooperative purchasing alliances administered by state procurement offices. Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represent the jurisdictions active in recent solicitations.

Activity concentrates in Florida and Minnesota, with MMCAP's reach extending to participating state and local government facilities including Oregon. Seminole County released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries, with a July 26, 2023 response deadline and a two-year initial term plus one-year renewal option. MMCAP issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with proposals due March 26, 2026 and awards effective July 1, 2026. Both solicitations require vendors to maintain comprehensive insurance, comply with FDA and drug supply chain regulations, and demonstrate pricing flexibility; the MMCAP RFP emphasizes cGMP certification, EDI capability, and pricing competitiveness weighted at 75 percent of evaluation.